Pharmaceutical

Stock drama, cancer vaccine success, and new science — ...

There was some drama at the American Association for Cancer Research annual meet...

Opinion: Judicial overreach is an immediate hazard to a...

It is reckless for courts to make decisions that disregard decades of clinical e...

Tubulis and Bristol Myers Squibb agree to develop ADCs ...

Bristol Myers Squibb will be solely responsible for the development, production ...

Targovax announces plans to rebrand as Circio

Circio will initially focus on developing new circRNA medicines for cancer, with...

Zucara Therapeutics receives FDA IND approval for ZT-01

The FDA IND approval allows Zucara to begin its Phase IIa ZONE trial of ZT-01 in...

Maxion scoops £2m UK grant to develop autoimmune diseas...

The grant was awarded as part of an Innovate UK competition and will support Max...

DBV sets course on regulatory journey for peanut allerg...

Following several setbacks, the DBV now has received guidance to submit addition...

Abdera raises funds to advance radiopharmaceuticals to ...

Abdera’s ROVEr platform facilitates the development of next-generation antibody-...

Hasten Biopharmaceutic raises $315m for pipeline assets...

Hasten will also use the proceeds from the round to fund future acquisitions.

The next phase of decentralisation in clinical trials

There were 250 decentralised clinical trials (DCTs) worldwide in 2012. By 2021, ...

Amgen scores Otezla patent win in court to keep competi...

The US Court of Appeals hands Amgen a patent win for Otezla, as the psoriasis ma...

Forbion raises $1.47bn for two life sciences-focused funds

The two funds both exceeded their original target sizes and attracted new invest...

Study: Black women should start breast cancer screening...

Breast cancer is slightly less prevalent among Black women in the U.S. compared ...

STAT+: Congress targets reducing hospital outpatient pa...

House legislators are floating aggressive “site-neutral” bills targeting large h...

FDA’s new plan to study opioids’ effectiveness faces re...

A contentious hearing was the latest chapter in a long-running debate about the ...

STAT+: FDA’s Califf talks cell and gene therapies, abor...

FDA Commissioner Robert Califf took questions on everything from cell and gene t...